about
A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 studyP2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.Circulating heat shock protein 60 levels are elevated in HIV patients and are reduced by anti-retroviral therapyEarly loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART)Focal bone lesions in HIV-positive patient treated with tenofovirPrevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.B Cell Production of Both OPG and RANKL is Significantly Increased in Aged MiceAntiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients.Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss.HIV and its effects on bone: a primer for rheumatologistsInterventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals.Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infectionOSTEOPONTIN: A KEY LINK BETWEEN IMMUNITY, INFLAMMATION AND THE CENTRAL NERVOUS SYSTEM.The protease inhibitors and HIV-associated bone loss.Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudyLow baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationThe Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options.Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.Role of inflammation in HIV-1 disease progression and prognosis.[HIV infection : chronic disease with comorbidities].Bone Loss in HIV Infection.Physiological and pathophysiological bone turnover - role of the immune system.Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.HIV: an underrecognized secondary cause of osteoporosis?Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss.T-cell receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts.Management of Reduced Bone Mineral Density in HIV: Pharmacological Challenges and the Role of Exercise
P2860
Q28534700-EC68A2E9-7B4F-4ECD-8BDA-BBD85AA45D47Q34261784-077F2099-DE24-450D-9E77-F560032397A4Q34428634-92334090-3A19-4BED-880F-F8C5C88E803AQ34786514-567FA105-7CC7-4C9B-B476-9BACAD5A0148Q35096244-709E0AFE-3C8B-4CC4-B93D-1D18667832B1Q35112499-BAF24A6A-EE29-41D7-9CF8-E87BE1A41376Q35124970-6DF1BDA8-3329-4195-B5A2-CBEEDDB7ECC2Q35505203-2D8F1A17-2266-47A7-BBCC-94DB5C66FB77Q35598428-5BF58BBD-8928-44EF-B878-DDA2065DACE9Q35859876-83327FC0-AB89-4875-A99C-54AE043E7D94Q35861528-C7590F29-4B22-4A0F-8FB9-D764C3AA6C05Q36078749-0769925E-2B58-4158-BFC5-341764C05451Q36087907-D900F17F-6D34-40A5-BE10-D776DD5C639EQ36381079-27D7DF4A-D01B-4E21-8778-4E2C77284DDCQ36381307-9C3B7FB0-5EC5-48AA-A1FD-4A83FF7FFCACQ36462148-20DF48A1-0F75-4B64-8CA3-BBB97358E69DQ36739654-0845781D-54B5-4920-A49F-5F5C0FD1B199Q36818259-346266A0-C26D-44B3-8303-BD1870D2AC0EQ36853309-373FD7F1-0608-46CB-9A23-ECE54B0DE139Q37247235-859C3EED-6291-4AA1-AE89-92CEEC1B7ADDQ37287589-94342397-A206-410F-9FD1-6F6B9244A17FQ37344527-83C0A755-A315-48C9-8A2D-C8D563A55C32Q37589696-05CE277E-A07C-4272-B52F-AD30D5EDB8F3Q38040137-60AE1BD7-3A1D-44AD-94F7-2666102D9721Q38055705-BFCC6432-5C8A-46D7-BF65-7590EB795CADQ38177684-F5CA4D2D-AC12-41E6-8673-70859FBC8CB2Q38183454-356DA0A7-3B84-46A3-AAA1-1205A1E8D54FQ38413754-6F7F29D1-35D7-4E2B-9240-9FC2FBA51A78Q38835028-2D8E2A88-8808-4949-AE63-5C0972BE6B67Q38867785-C6482ED3-62E9-46DE-B3C8-E54529A696D3Q41647237-B52B2140-57B4-4046-80FF-79A2930B25C6Q45374537-CABCB572-99EC-4F44-A620-B15CF012C68AQ47194100-17EF08B3-6623-4D20-8783-3968F924DD86Q50051644-C0FC0DA3-8E37-4785-93A9-3F904B47BA42Q56984507-8FCC313B-B14F-45D9-ACE9-409C002626D5
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
HIV: inflammation and bone
@ast
HIV: inflammation and bone
@en
HIV: inflammation and bone
@nl
type
label
HIV: inflammation and bone
@ast
HIV: inflammation and bone
@en
HIV: inflammation and bone
@nl
prefLabel
HIV: inflammation and bone
@ast
HIV: inflammation and bone
@en
HIV: inflammation and bone
@nl
P2093
P2860
P1476
HIV: inflammation and bone
@en
P2093
Emily McIntosh
Ighovwerha Ofotokun
M. Neale Weitzmann
P2860
P2888
P356
10.1007/S11904-011-0099-Z
P407
P577
2012-03-01T00:00:00Z
P5875
P6179
1033551565